Periocular sebaceous carcinoma: updates in the diagnosis, treatment, staging, and management.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
13 Feb 2024
13 Feb 2024
Historique:
revised:
05
01
2024
received:
31
10
2023
accepted:
08
01
2024
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
aheadofprint
Résumé
Periocular sebaceous carcinoma (PSC) is a rare, aggressive, and potentially metastatic adnexal malignancy. Due to the ability of PSC to resemble several benign and malignant conditions, diagnosis is often delayed or mistaken. In addition, even with a known diagnosis, choosing the right treatment is still an open debate. For this reason, we decided to review the most up-to-date literature on PSC and propose a dedicated procedural protocol to help clinicians when dealing with PSC. A PubMed search was carried out using the terms "Sebaceous Carcinoma", "Adnexal Periocular Cancer", "Sebaceous Carcinoma AND eyelid", "Periocular Sebaceous Carcinoma", and "Ocular Adnexa". Pertinent studies published in English from 1997 up to December 2022 were compared to the selection criteria and if suitable, included in this review. Through the initial search, 84 articles were selected. Of these, 36 were included in the final study. Several papers explored different diagnostic and therapeutic strategies regarding PSC diagnosis and management. In light of the current literature review and the multidisciplinary experience of three clinical centers, a dedicated procedural protocol is proposed. PSC diagnosis may be achieved through accurate clinical evaluation, but it requires histopathologic confirmation, which can be challenging. Dermoscopy, in vivo reflectance confocal microscopy, and optical coherence tomography may facilitate PSC clinical examination, while immunohistochemistry stains may support histological diagnosis. Appropriate disease staging is necessary before choosing the treatment, as local disease requires radically different treatment compared to advanced disease. In addition, recent innovations in nonsurgical treatments, including radio-chemotherapy, immunotherapy, and targeted therapy, may be a viable option in the most challenging cases.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 the International Society of Dermatology.
Références
Snow SN, Larson PO, Lucarelli MJ, Lemke BN, Madjar DD. Sebaceous carcinoma of the eyelids treated by mohs micrographic surgery: report of nine cases with review of the literature. Dermatol Surg. 2002;28(7):623-631.
Niinimäki P, Siuko M, Tynninen O, Kivelä TT, Uusitalo M. Sebaceous carcinoma of the eyelid: 21-year experience in a Nordic country. Acta Ophthalmol. 2021;99(2):181-186.
Schmitz EJ, Herwig-Carl MC, Holz FG, Loeffler KU. Sebaceous gland carcinoma of the ocular adnexa-variability in clinical and histological appearance with analysis of immunohistochemical staining patterns. Graefes Arch Clin Exp Ophthalmol. 2017;255(11):2277-2285.
Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology. 2004;111(12):2151-2157.
Kruse R, Rütten A, Lamberti C, Hosseiny-Malayeri HR, Wang Y, Ruelfs C, et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet. 1998;63(1):63-70.
Brady KL, Hurst EA. Sebaceous carcinoma treated with Mohs micrographic surgery. Dermatol Surg. 2017;43(2):281-286.
Zhou C, Shi Y, Chai P, Wu F, Xia W, He X, et al. Contemporary update of overall prognosis and nomogram to predict individualized survival for Chinese patients with eyelid sebaceous carcinoma. EBioMedicine. 2018;36:221-228.
Muqit MM et al. Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma. Br J Ophthalmol. 2013;97(1):47-51.
Sahu SK, Sen S, Poddar C. Sebaceous gland carcinoma of lid: masquerading as a recurring Chalazion. Int J Appl Basic Med Res. 2021;11(2):117-119.
Kan LW, Leu YS, Tzen CY, Wu CH. Recurrent sebaceous gland carcinoma of eyelid previously diagnosed as basal cell carcinoma: case report. Am J Otolaryngol. 2011;32(6):620-623.
Satomura H, Ogata D, Arai E, Tsuchida T. Dermoscopic features of ocular and extraocular sebaceous carcinomas. J Dermatol. 2017;44(11):1313-1316.
Moscarella E, Argenziano G, Longo C, Cota C, Ardigò M, Stigliano V, et al. Clinical, dermoscopic and reflectance confocal microscopy features of sebaceous neoplasms in Muir-Torre syndrome. J Eur Acad Dermatol Venereol. 2013;27(6):699-705.
Bergeron S, Arthurs B, Sanft DM, Mastromonaco C, Burnier Jr MN. Optical coherence tomography of peri-ocular skin cancers: an optical biopsy. Ocul Oncol Pathol. 2021;7(2):149-158.
Mittal R, Araujo I, Czanner G, Coupland SE. Perforin expression in eyelid sebaceous carcinomas: a useful and specific immunomarker for the differential diagnosis of eyelid carcinomas. Acta Ophthalmol. 2016;94(5):e325-e330.
Cabral ES, Auerbach A, Killian JK, Barrett TL, Cassarino DS. Distinction of benign sebaceous proliferations from sebaceous carcinomas by immunohistochemistry. Am J Dermatopathol. 2006;28(6):465-471.
Roberts ME, Riegert-Johnson DL, Thomas BC, Thomas CS, Heckman MG, Krishna M, et al. Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms. J Genet Couns. 2013;22(3):393-405.
Na HY, Choe JY, Shin SA, Choung HK, Oh S, Chung JH, et al. Proposal of a provisional classification of sebaceous carcinoma based on hormone receptor expression and HER2 status. Am J Surg Pathol. 2016;40(12):1622-1630.
Peterson C, Moore R, Hicks JL, Morsberger LA, de Marzo AM, Zou Y, et al. NGS analysis confirms common TP53 and RB1 mutations, and suggests MYC amplification in ocular adnexal sebaceous carcinomas. Int J Mol Sci. 2021;22(16):8454.
Reynolds RR, Davies MJ, Buffam FV, Dolman PJ, White VA. Differences in 7th and 8th edition American Joint Committee on Cancer staging for periocular sebaceous carcinoma. Can J Ophthalmol. 2021;56(1):31-36.
McConnell LK, Syed NA, Zimmerman MB, Carter KD, Nerad JA, Allen RC, et al. An analysis of conjunctival map biopsies in sebaceous carcinoma. Ophthalmic Plast Reconstr Surg. 2017;33(1):17-21.
Savar A, Oellers P, Myers J, Prieto VG, Torres-Cabala C, Frank SJ, et al. Positive sentinel node in sebaceous carcinoma of the eyelid. Ophthalmic Plast Reconstr Surg. 2011;27(1):e4-e6.
Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005;50(2):103-122.
Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol. 2008;47(3):276-279.
Bonavolontà P, Dell'Aversana Orabona G, Abbate V, Iaconetta G, Bonavolontà G, Califano L. Treatment of metastatic eyelid carcinoma. J Craniofac Surg. 2017;28(8):e722-e725.
Mahipathy SR et al. Sebaceous gland carcinoma of the lower eyelid reconstructed with a composite flap: a case report. J Clin Diagn Res. 2016;10(6):PD16-8.
Chang HH, Suh E, Fortes BH, Zheng F, Cheng A. Forehead galeal pericranial flap for single-staged total upper eyelid reconstruction in sebaceous gland carcinoma excision. Int Med Case Rep J. 2017;10:309-312.
Takahashi Y, Takahashi E, Nakakura S, Kitaguchi Y, Mupas-Uy J, Kakizaki H. Risk factors for local recurrence or metastasis of eyelid sebaceous gland carcinoma after wide excision with paraffin section control. Am J Ophthalmol. 2016;171:67-74.
Hou JL, Killian JM, Baum CL, Otley CC, Roenigk RK, Arpey CJ, et al. Characteristics of sebaceous carcinoma and early outcomes of treatment using Mohs micrographic surgery versus wide local excision: an update of the Mayo Clinic experience over the past 2 decades. Dermatol Surg. 2014;40(3):241-246.
Lam SC, Li EYM, Yuen HKL. 14-year case series of eyelid sebaceous gland carcinoma in Chinese patients and review of management. Br J Ophthalmol. 2018;102(12):1723-1727.
Song A, Carter KD, Syed NA, Song J, Nerad JA. Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes. Ophthalmic Plast Reconstr Surg. 2008;24(3):194-200.
Kovacevic PT, Visnjic MM, Kovacevic TT, Radojkovic MR, Stojanovic MR. Extended orbital exenteration in the treatment of advanced periocular skin cancer with primary reconstruction with a galeacutaneous flap. Scand J Plast Reconstr Surg Hand Surg. 2009;43(6):325-329.
Tyers AG. Orbital exenteration for invasive skin tumours. Eye. 2006;20(10):1165-1170.
Gerring RC, Ott CT, Curry JM, Sargi ZB, Wester ST. Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival. Eye. 2017;31(3):379-388.
Belaid A, Nasr C, Benna M, Cherif A, Jmour O, Bouguila H, et al. Radiation therapy for primary eyelid cancers in Tunisia. Asian Pac J Cancer Prev. 2016;17(7):3643-3646.
Hata M, Koike I, Omura M, Maegawa J, Ogino I, Inoue T. Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. Int J Radiat Oncol Biol Phys. 2012;82(2):605-611.
Takagawa Y, Tamaki W, Suzuki S, Inaba K, Murakami N, Takahashi K, et al. Radiotherapy for localized sebaceous carcinoma of the eyelid: a retrospective analysis of 83 patients. J Radiat Res. 2019;60(5):622-629.
Callahan EF, Appert DL, Roenigk RK, Bartley GB. Sebaceous carcinoma of the eyelid: a review of 14 cases. Dermatol Surg. 2004;30(8):1164-1168.
Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol. 2001;44(6):1004-1009.
Ota S, Sakamoto T, Ochiai R, Haruyama T, Ishihara M, Natsume M, et al. Successful treatment with taxane-based chemotherapy in advanced sebaceous carcinoma: a case report and literature review. Case Rep Oncol. 2019;12(1):47-52.
Kaliki S, Ayyar A, Nair AG, Mishra DK, Reddy VAP, Naik MN. Neoadjuvant systemic chemotherapy in the management of extensive eyelid sebaceous gland carcinoma: a study of 10 cases. Ophthalmic Plast Reconstr Surg. 2016;32(1):35-39.
Bowen RC, Lawson BM, Jody NM, Potter HD, Lucarelli MJ. The programmed death pathway in ocular adnexal sebaceous carcinoma. Ophthalmic Plast Reconstr Surg. 2020;36(1):74-79.
Domingo-Musibay E, Murugan P, Giubellino A, Sharma S, Steinberger D, Yuan J, et al. Near complete response to pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. J Immunother Cancer. 2018;6(1):58.
Woods AD, Grushchak S, Williams KM, Tan A, Krunic AL. Combination treatment of bilateral periocular sebaceous carcinomas with microsatellite instability with neoadjuvant pembrolizumab and Mohs surgery. Australas J Dermatol. 2022;63(4):e345-e349.
Bladen JC, Moosajee M, Tracey-White D, Beaconsfield M, O'Toole EA, Philpott MP. Analysis of hedgehog signaling in periocular sebaceous carcinoma. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):853-860.
Ito T et al. NECTIN4 expression in sebaceous and sweat gland carcinoma. Eur J Dermatol. 2022;32(2):181-186.
de Giorgi V et al. The burden of cutaneous adnexal carcinomas and the risk of associated squamous cell carcinoma: a population-based study. Br J Dermatol. 2019;180(3):565-573.
Nijhawan N, Ross MI, Diba R, Gutstein BF, Ahmadi MA, Esmaeli B. Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a cancer center. Ophthalmic Plast Reconstr Surg. 2004;20(4):291-295.
Dogru M, Matsuo H, Inoue M, Okubo K, Yamamoto M. Management of eyelid sebaceous carcinomas. Ophthalmologica. 1997;211(1):40-43.
Kaliki S, Pyda S, Goel N, Dave TV, Naik MN, Mishra DK. Malignant eyelid tumors: are intra-operative rapid frozen section and permanent section diagnoses of surgical margins concordant? Int Ophthalmol. 2019;39(10):2205-2211.
Hewes EH, Sullivan JH, Beard C. Lower eyelid reconstruction by tarsal transposition. Am J Ophthalmol. 1976;81(4):512-514.